Beijing, Mar 24 (Prensa Latina) Chinese pharmaceutical company Sinovac assured that its vaccine against Covid-19 is basically safe and effective in teenagers and children, and the first two stages of trials showed a low percentage of significant adverse effects.
According to CEO Zeng Gang, they tested the product with different doses in 552 children between three and 17 years of age, only two children had fever and all of them developed antibodies.
The company sent the data to Chinese regulators and is analyzing the appropriate amount of doses for each age group, while continuing with the last phase of research.
Apart from Sinovac, its similar Sinopharm is also conducting studies in minors of the vaccines obtained to prevent Covid-19.
China inoculated more than 75 million adults and this week accelerated the nationwide campaign with the idea of protecting 40 percent of the population by next June and then reaching immunity of the people by early 2022.
The Government now considers the program a political task and the priority of all provincial administrations, which involves the mobilization of leaders from the communities.
In this context, vaccination was extended to universities, diplomatic staff and officials from other countries based in Beijing.
- Countries: None